<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1725">
  <stage>Registered</stage>
  <submitdate>22/10/2007</submitdate>
  <approvaldate>22/10/2007</approvaldate>
  <nctid>NCT00548808</nctid>
  <trial_identification>
    <studytitle>A Study for Type 2 Diabetic Patients</studytitle>
    <scientifictitle>Comparison of Insulin Lispro Low Mixture With Insulin Glargine When Initiating and Intensifying Insulin Therapy As Required in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Oral Antihyperglycemic Medication</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>F3Z-CR-IOPH</secondaryid>
    <secondaryid>11541</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Insulin lispro low mixture
Treatment: drugs - Insulin glargine
Treatment: drugs - Insulin lispro

Experimental: Insulin lispro low mixture - Insulin lispro low mixture (1, 2 or 3 daily injections)

Active Comparator: Insulin glargine - Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)


Treatment: drugs: Insulin lispro low mixture
Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.

Treatment: drugs: Insulin glargine
Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks

Treatment: drugs: Insulin lispro
Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c)</outcome>
      <timepoint>Baseline, 48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Hemoglobin A1c (HbA1c) Over Time</outcome>
      <timepoint>Baseline, 16 Weeks, 32 Weeks, 48 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients Achieving HbA1c &lt;6.5% and &lt;7% Over Time</outcome>
      <timepoint>16 weeks, 32 weeks, 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>7-point Self-monitored Blood Glucose Profiles</outcome>
      <timepoint>Baseline, 16 weeks, 32 weeks, 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Postprandial Blood Glucose Over Time - The change in blood glucose was evaluated by the GlycoMark test. GlycoMark measures levels of 1,5 anhydroglucitol (1,5 AG) in serum or plasma, allowing for the short- to intermediate-term monitoring of glycemic control in patients with diabetes. When 1,5 AG values decrease, serum glucose levels increase.</outcome>
      <timepoint>Baseline, 16 weeks, 32 weeks, 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily Total Insulin Dose (U/Day) at 16, 32, and 48 Weeks</outcome>
      <timepoint>16 weeks, 32 weeks, 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily Total Insulin Dose Per Body Weight (U/kg/Day) at 16, 32, and 48 Weeks</outcome>
      <timepoint>16 weeks, 32 weeks, 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline to 48 Week Endpoint in Lipid and Cholesterol Profiles</outcome>
      <timepoint>baseline, 48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Number of Participants With Serious and Non-Serious Adverse Events - Safety was assessed via serious adverse events (SAEs) and AEs, the details of which are listed in the Reported Adverse Event section.</outcome>
      <timepoint>baseline through 48 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes mellitus

          -  Receiving oral antihyperglycemic medications (including metformin) without insulin
             injection in the last 90 days

          -  Hemoglobin A1c (HbA1c) equal to or greater than 7.0% but less than 11.0%

          -  Willing to receive insulin injection while continuing to take the prestudy oral
             antihyperglycemic medications

          -  Able to perform self monitoring of blood glucose</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Are taking any other glucose-lowering agents other than metformin, sulfonylurea or
             Thiazolidinedione (Pioglitazone)

          -  Have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in
             the past 6 weeks, or for a total of 30 days or more, in the last 24 weeks

          -  Have a body mass index greater than 35 kg/m2

          -  History or presence of kidney disease

          -  Have cardiac disease (Class III or IV)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>426</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Daw Park</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - East Ringwood</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands</hospital>
    <postcode>5041 - Daw Park</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Belem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Campinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Fortaleza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Prince Edward Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guang Zhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Aligarh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Coimbatore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Trivandrum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Kyunggi-Do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily
      injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections)
      on lowering the blood sugar level</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00548808</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM- 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>